AB0511 EFFECT OF SECUKINUMAB ON THE REDUCTION OF MYOCARDIAL DYSFUNCTION IN PATIENTS WITH ANKYLOSING SPONDYLITIS

Background: In ankylosing spondylitis (AS), early subclinical changes in the myocardium mostly remain undiagnosed. The impact of genetic engineering biological therapy on these is also unclear. Objectives: Aim: to establish relationship between taking secukinumab and systolic diastolic myocardial function patients with AS. Methods: 69 AS were examined, which first group included 33 people (average age 38.8±4.74, 63.6% men) who received interleukin 17 inhibitor (IL17) - secukinumab, second 36 did not receive therapy, average 42.5±11 years, 66.7% men. control 40 healthy individuals, comparable gender age. Patients underwent tissue dopplerography heart transthoracic echocardiography. research materials subjected statistical processing using program STATISTICA 10.0. Results: had significantly higher left ventricular mass index ejection fraction (p<0.01) compared group. Moreover, among do take indicators highest (tabl.1). Table 1. Comparison echocardiography parameters study groups according Craskell-Wallis test. Показатель 1 2 р LVMI 85 [81; 100] 93 [81,3; 114,2] 79,5 [72; 86,5] р=0,002 EF 63 [62; 64] 64,5 [63; 66] 60 [59,5; 64,5] р=0,003 – index, fraction. A comparison established statistically values peak velocity ring mitral valve diastole (e’L) 1st (14 [9,5; 14]) (13 [11; 15,5]) indicator (10,5 [8,3; 13]), p<0,01; speed movement septum diastole, (e’S) (11 [9; 11]) 2th (8.1 [7; 12]) 10 [8.5; 11]), p<0.05, 2nd lower than (p=0.03). Significant differences supported by a frequency detection dysfunction groups. Diastolic was diagnosed only this 38.9%. Against background use an increase revealed. Conclusion: are characterized high dysfunction. Inhibition IL17 can reduce dysfunction, confirmed improvement contractility during therapy. References: [1]ankylosing spondylitis, spondylarthritis, Disclosure Interests: None declared.